Merit Medical releases 12-month efficacy results of WRAPSODY WAVE trial
Systems announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy trial ...
Zacks Investment Research on MSN12d
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
Merit Medical Systems MMSI released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), ...
Medscape7d
Regional Anesthesia: Preferred Technique for Venodilatation in the Creation of Upper Extremity Arteriovenous Fistulae
Accesses placed included 20 radiocephalic AVF, 8 brachiobasilic AVF, 8 brachiocephalic AVF, 2 arteriovenous grafts ... and may allow more options for access placements. However, these patients ...
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 ...
Endovascular Today13d
Merit’s Wrapsody CIE Evaluated in 12-Month Efficacy Data From WAVE
Merit Medical Systems, Inc. announced the publication of the 6-month results from the randomized arm of the WAVE trial of arterio ...